Drug Information

Drug General Information
Drug ID
D00DYK
Former ID
DIB009141
Drug Name
Lunacalcipol
Synonyms
CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma
Drug Type
Small molecular drug
Indication Psoriasis [ICD9: 696; ICD10:L40] Phase 2 [523662]
Company
Johns Hopkins University
Structure
Download
2D MOL

3D MOL
Formula
C28H42O4S
Canonical SMILES
[C@@]12([C@H](/C(=C/C=C/3\C(=C)[C@H](C[C@@H](C3)O)O)/CC<br />C2)CC=C1[C@@H](C/C=C/S(=O)(=O)C(C)(C)C)C)C
PubChem Compound ID
10672195
Target and Pathway
Target(s) Cytochrome P450 24 Target Info Inhibitor [548167]
KEGG Pathway Steroid biosynthesis
Metabolic pathways
MicroRNAs in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Vitamin D metabolism and pathway
Reactome Vitamin D (calciferol) metabolism
WikiPathways Metapathway biotransformation
Oxidation by Cytochrome P450
Nuclear Receptors in Lipid Metabolism and Toxicity
Vitamin D Receptor Pathway
Metabolism of steroid hormones and vitamin D
Phase 1 - Functionalization of compounds
Vitamin D Metabolism
References
Ref 523662ClinicalTrials.gov (NCT01453634) Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018). U.S. National Institutes of Health.
Ref 548167Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022679)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.